In 2018 the International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Read more
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International.* Read more
The clinical significance of osteoporosis lies in the painful, debilitating fractures that arise, which are a major cause of long-term disability in the population. Nevertheless, osteoporosis is under-diagnosed and undertreated: in the European Union, it is estimated that 57 % of women at high risk of fragility fracture due to osteoporosis do not receive bone-specific treatment. Read more
algorithm management of fracture risk in osteoporosis
Fragility fractures are a serious yet neglected complication of both type 1 and type 2 diabetes, with increased risk of fragility fractures in people with diabetes extending across the life span. Read more
Leading expert, Prof. Nick Harvey, Professor of Rheumatology and Clinical Epidemiology, Honorary Consultant Rheumatologist at the University of Southampton (UK), Vice Chair of IOF’s Committee of Scientific Advisors (CSA), will be the speaker of this much anticipated 1-hour Capture the Fracture® webinar. WHEN: January 16, 11:00-12:00 CET Read more
On April 28th, the U.S. Food and Drug Administration (FDA) approved Abaloparatide, a new osteoanabolic agent for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture — patients who have had a prior osteoporotic fracture, have multiple fracture risk factors, or have failed or cannot tolerate other osteoporosis therapies. Read more
El 28 de abril pasado, la Administración de Drogas y Alimentos de los Estados Unidos (FDA) aprobó el Abaloparatide. Se trata de un nuevo agente osteoanabólico para el tratamiento de mujeres posmenopáusicas con osteoporosis y que tienen un alto riesgo de fractura como aquellas pacientes que tuvieron una fractura osteoporótica previa, que presentan múltiples factores de riesgo de fractura o que han... Read more
A new Position Statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated by aromatase-inhibitors (AI) and outlines key management strategies to help prevent bone loss and related fractures. Read more
IOF is pleased to announce that the UK National Osteoporosis Guideline Group (NOGG) 2017 Update has now been released via the NOGG website (  This new Guideline, accredited by NICE, includes a number of updates on risk assessment, management and treatments. Read more
Las fracturas de cadera son el tipo más severo de fractura en pacientes osteoporóticos y presentan una gran preocupación. En general, conducen a discapacidad física a largo plazo, disminuyen la capacidad para llevar a cabo las actividades diarias y vivir independientemente, reducen la calidad de vida y están asociadas a muerte prematura. En el mundo occidental, el riesgo de fracturas de cadera en... Read more


Subscribe to Treatment